|
Diabetes
|
0.090 |
Biomarker
|
disease |
BEFREE |
Preliminary additional analysis from this large cohort indicates that PNPLA3 GG carriers (8.2%) drink significantly less high percentage beverages (23% vs 55%, p < 0.001) but show no metabolic phenotype such as increased weight, BMI or diabetes.
|
30362098 |
2019 |
|
Diabetes
|
0.090 |
Biomarker
|
disease |
BEFREE |
PNPLA3 GG genotype carriers showed greater increases in the LFC and serum alanine aminotransferase (ALT) but lower PBG elevation and incident diabetes than PNPLA3 wild-type (CC) genotype carriers exhibiting the same degree of body weight increase.
|
30673802 |
2019 |
|
Diabetes
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Patients with NASH cirrhosis and cryptogenic cirrhosis were of a similar age and gender, as well as having a similar body mass index, PNPLA3 rs738409 genotype, and prevalence of diabetes (p >0.05).
|
30144554 |
2018 |
|
Diabetes
|
0.090 |
Biomarker
|
disease |
BEFREE |
Logistic regression analysis showed that FINS, ADPN, HOMA-R, CPR, duration of diabetes mellitus and BMI had independently predictive value for diabetes complicated with CHD (P<0.05).
|
30186434 |
2018 |
|
Diabetes
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, PNPLA3, and to a lesser extent, MBOAT7 variants are associated with NAFLD risk and modulate liver injury in non-obese patients without diabetes.
|
29483677 |
2018 |
|
Diabetes
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that the liver expression of the PNPLA3 p.148M variant confers a genetic predisposition to liver graft steatosis along with nutritional status and diabetes.
|
29396131 |
2018 |
|
Diabetes
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
When patients were grouped according to their diabetes status, the PNPLA3 genetic variants were associated with advanced liver fibrosis in diabetic patients only, but not in non-diabetic patients.
|
25457210 |
2015 |
|
Diabetes
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, PNPLA-3 non-CC genotype is associated with posttransplant obesity but not independently with diabetes/IFG.
|
23859071 |
2013 |
|
Diabetes
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
In the whole series combined, adiponutrin genotype was associated with steatosis grade >1 (OR = 1.35, 95% CI = 1.04-1.76), nonalcoholic steatohepatitis (OR = 1.5, 95% CI = 1.12-2.04), and fibrosis stage >1 (OR = 1.5, 95% CI = 1.09-2.12), independent of age, body mass index, and diabetes.
|
20373368 |
2010 |